BioCentury
ARTICLE | Company News

EpiCept neurology news

January 16, 2012 8:00 AM UTC

EpiCept engaged SunTrust Robinson Humphrey to advise on maximizing the commercial value of AmiKet, a topical cream containing amitriptyline and ketamine. EpiCept said it is in partnering discussions for AmiKet and plans to begin a Phase III trial next quarter to treat chemotherapy-induced peripheral neuropathy (CIPN) following taxane-based therapy. ...